Multiple intrinsic and extrinsic mechanisms contribute to vulnerability of cognitive decline and nurses play a significant role in assisting individuals and families to use strategies for healthy cognitive aging. The objective of this narrative review is to provide a synthesis of the intrinsic and extrinsic mechanisms of cognitive decline and conditions that are associated with cognitive decline.
INTRODUCTION
Cognitive function is a critical component of healthy aging and a major concern for the growing number of older adults who will make up 20% of the population by the year 2030. 1 Healthy aging entails the maintenance of neurocognitive function, although minor deficiencies in visuospatial function, conceptual reasoning, memory, and processing speed are expected as adults enter the later years of life. 2 However, cognitive decline that impairs the ability to perform activities of daily living most likely represent the effect of comorbid disease. 3 This is of particular importance, since older adults are living longer but have a higher prevalence of comorbidities that can place them at risk of cognitive decline with potential progression to mild cognitive impairment (MCI) and dementia.
While the number, type, and severity of comorbidities are factors to consider in the risk of cognitive decline, there are also risk factors along the life span that may increase vulnerability to accelerated brain aging. Both intrinsic (i.e., genomic) and extrinsic (i.e., comorbidities, lifestyle, environment) mechanisms impact vulnerability to cognitive decline, and may one day be quantified to inform individual health promotion/disease prevention decisions regarding cognitive health and generate new strategies to retain cognitive function into the extremes of old age. In this review, the different definitions of cognitive decline and relevant comorbidities and exposures that may impact the trajectory of cognitive decline over the life span are examined. Emerging areas of research are discussed that will likely facilitate new insights and the translation of current knowledge into clinical practice.
DEFINING COGNITIVE DECLINE
Cognition is measured through testing mental status, verbal and nonverbal learning, memory, attention, executive function, language, visuospatial abilities, intelligence, and functional assessments. In primary clinical settings, it is often difficult to recognize changes in cognition, although routine use of the mini mental status examination (MMSE) for older adults may help to identify changes over time. However, it has been noted that changes in the MMSE likely represent the onset of neurodegenerative processes that are at a stage of limited amenability. 1 In order to identify the early trajectory of cognitive decline, when secondary interventions may be implemented before neuronal damage becomes irreversible, the diagnostic category of MCI was developed ( 4 MCI represents a high-risk group because dementia develops at a rate of 10-15% per year as compared to the general population of 1-2%. The incidence of MCI is higher in males compared to females and twice as high in subjects with <12 years of education compared to participants with >12 years of education.
Interventions developed for individuals with MCI have not been successful in decreasing the rate of conversion to dementia, most likely because extensive neuronal loss has already occurred by the time MCI is recognized. 4 These findings prompted efforts to operationalize a pre-MCI stage, which focuses on subjective cognitive complaints, defined as self-or informant-reported cognitive disturbances occurring in the absence of an objective impairment in cognitive performance. 5 However, in clinical studies self-and informant-based subjective decline correlate with greater psychological distress and only slightly lower cognitive performance. 6 Longitudinal studies, in contrast to cross-sectional analyses, have reported a strong association between subjective memory complaints and the development of cognitive decline or dementia over a period of 1-7 years. 7 However, psychological distress is strongly associated with subjective memory complaints, vascular risk factors are only weakly associated with self-reported cognitive decline. 6 Overall subjective cognitive complaints have been suggested as a risk factor of cognitive decline, and led to development of early and late MCI definitions (Table 1 ). Yet, the complexity of applying these definitions in clinical practice has hindered early recognition and prompt intervention in clinical practice settings. 4 More recently, the concept of cognitive frailty, 
PROTECTIVE AND RISK FACTORS
Strategies to preserve cognitive function are rarely discussed beyond maintaining baseline weight and blood pressure. 8 However, cardiometabolic risk factors of cognitive decline are commonly cited in the literature, including vascular risk factors (hypertension, elevated lipid panel, metabolic syndrome), comorbid conditions such as obesity and diabetes, and genetic risk factors, mainly the APOE genotype. 9, 10 Adiposity, diabetes, heart failure (HF), and stroke are risk factors for nonamnestic MCI, whereas HF and stroke are risk factors of functional decline. 11 In contrast to younger populations, systolic blood pressure (SBP), and pulse pressure (PP), readings among the oldest old (over age 85) are positively associated with resiliency to physical and cognitive decline, particularly in individuals with pre-existing physical disability. In the oldest old, SBP and PP are associated with lower annual increases in disability and MMSE scores. 12 In addition to cardiometabolic factors, keeping the brain active through engaging in new activities, regular sleep cycles, and cardiovascular exercise help to maintain cognition. 13 Leisure activities, whether they are mental, physical, and/or social, protect cognitive function in older adults. 14 Lifestyle behaviors, such as sleep, can also influence cognitive decline-difficulty initiating sleep and early morning awakening has been associated with amnestic MCI and difficulties in maintaining sleep with nonamnestic MCI. 15 Cognitively normal older adults who report higher levels of physical activity may have slightly better cognitive performance, but the potential cognitive benefits of higher levels of physical activity over time may be most evident in individuals at genetic risk for Alzheimer's disease (APOE 4 carriers). 16 In addition, interactions among depressive symptoms, APOE 4 allele, and cognitive decline were demonstrated in a prospective populationbased sample of individuals 65 years and above interviewed at 3-year intervals. Cognitive function decreased more rapidly in individuals with depression who had one or more copies of the APOE 4 allele compared to those with no depressive symptoms. For each additional symptom of depression, cognitive decline increased among those with no copies and more than doubled the rate of decline among those with one or more copies of the APOE 4 allele. 17 
MECHANISMS OF COGNITIVE DECLINE
Gray matter atrophy has been consistently regarded as the etiology of cognitive decline. However, in early stage Alzheimer's patients with decreased scores on the MMSE, atrophy of the white matter has also been described, particularly of the corpus callosum-the largest white matter fiber bundle of the brain. 18 However, how these changes While these pathways may explain the mechanisms of neuronal loss that contribute to cognitive decline, there is also the component of neuronal reserve to consider; that is, the amount of neuronal reserve may be more important than neuronal loss in dictating the rate of cognitive decline. It has been suggested that the density of noradrenergic neurons in the locus coeruleus is a structural component of neural reserve. More specifically, the locus coeruleus neuronal density, brainstem tangles, and brainstem Lewy bodies have independent associations with the rate of cognitive decline. Higher density of noradrenergic neurons in the locus coeruleus is associated with reduced cognitive decline even after accounting for common neurodegenerative lesions in these nuclei and elsewhere in the brain. 21 Brainstem tangles and plaques are commonly cited as a direct mechanism of cognitive decline. However, A-beta amyloid deposition measured by cerebrospinal fluid A-42, or Pittsburgh compound B positron emission tomography imaging, demonstrated that A-beta amyloid deposition initiates the pathological cascade, but is not the direct cause of cognitive impairment, whereas hippocampal atrophy indicates how far one is along the neurodegenerative path. 22 A-beta normally functions as an antimicrobial peptide in the innate immune system in response to clinically relevant pathogenic microorganisms.
A-beta monomers, dimers, and higher order oligomeric forms may be an early and toxic form of amyloid deposition.
APOE 4 carriers have a higher total amyloid load in Alzheimer's disease (AD), and in MCI display a higher amyloid burden; in presymptomatic APOE 4 carriers, there is reduced cerebral glucose metabolism, increased cerebral amyloid deposition, and enhanced cortical atrophy and accelerated memory decline. 23 In contrast, the DHCR24 gene appears to play a protective role and has been shown to confer resistance to A-beta and oxidative stress induced apoptosis by inhibiting caspase-3 activation. 24 The SORL1 gene is a neuronal receptor that binds ApoE and plays a crucial regulatory role in the processing of the amyloid precursor protein (APP); a mutation of this gene has been associated with increased vulnerability to AD. 24 Demyelination starts in the structures affected by neurofibrillary pathology and its presence correlates with the clinical picture of cognitive decline, indicating a mechanism of MCI-to-AD progression. 25 Demyelination of the medial temporal lobe and posterior structures, including white matter and gray matter, in single-and multiple-domain MCI has been demonstrated. 26 The spread of demyelination to prefrontal white matter and insula gray matter was seen in executive multidomain MCI. As these cellular and structural events progress, changes in brain function occur that manifest as cognitive decline. 25, 27 Comorbid conditions and various exposures throughout the life span contribute to the intrinsic and extrinsic mechanisms of cognitive decline described above. Studies that involve participants with some of the more well-known exposures and comorbidities that accelerate cognitive decline may provide valuable insights on how cumulative brain insults may be quantified as well as to test predictive models. Ultimately, the objective, mechanistic assessments could be used by nurses to guide the development of more targeted interventions as well as to evaluate the effect of the intervention on the mechanisms of cognitive decline.
TRAUMATIC BRAIN INJURY
Each year, an estimated 1.7 million American sustain traumatic brain injury (TBI) and there are current 5.3 million American living with TBI.
The pathophysiology of TBI has been described as a disease process in contrast to an event and may include short-and long-term sensorimotor, psychological and cognitive impairments. TBI is the best known established epigenetic risk factor for later development of neurodegenerative diseases and dementia. 28 People sustaining TBI are more shown that there may be some benefit to cognition in men and women.
In men, there were no differences in cognitive decline among alcohol abstainers, quitters, and light or moderate alcohol drinkers (<20 g/day) over 10 years. 30 However, alcohol consumption >36 g/day was associated with faster decline in all cognitive domains compared with consumption between 0.1 and 19.9 g/day over 10 years. In women, 10-year abstainers showed faster decline in the global cognitive score and executive function compared with those drinking 0.1-9.9 g/day of alcohol.
A second study showed that among women, a higher total consumption of alcoholic beverages was linearly associated with a smaller decline in global cognitive function with the smallest decline in the highest quantile corresponding to two to three glasses of alcoholic beverages per day. Women who drank about two to three glasses of alcoholic beverages per day showed less than half the decline in global cognitive function compared with those who drank no to very little alcohol. Individuals who drank 1.5 glasses of red wine per day showed a smaller decline in global cognitive function compared with those with the lowest consumption of red wine. 31 In contrast with moderated alcohol use, excessive alcohol exposure can lead to accelerated brain atrophy. Parahippocampal/hippocampal atrophy was specific to alcoholics with cognitive decline and atrophy of the thalamus and enlargement of the third ventricle was more severe in the cognitive decline group compared to the cognitively normal group. The parahippocampal and hippocampal cortices may play a crucial role in the retention of short-term memory in alcoholics. 32 In alcohol-dependent patients, trail making A, a test related to basic executive function, showed a correlation with insulin-like growth factor 1 (IGF-1). 33 Cocaine-dependent users display cognitive impairment in several areas of functioning that persists even after abstinence. 34 Specifically, attention, learning, memory, inhibitory control, and cognitive flexibility are often impaired in cocaine abusers. 35 Deficits in cognitive function are associated with marked white matter impairment in the prefrontal cortex (PFC) and altered serotonergic and dopaminergic function in the brain. 36 There was a consistent finding of poorer performance of the cocaine sample relative to cocaine and alcohol abusers on measures of complex psychomotor and simple motor functioning.
Pure cocaine abusers, but not abusers of both cocaine and alcohol, also performed more poorly than normal on a measure of global neuropsychological functioning. Vascular complications associated with cocaine use have been suggested as a possible mechanism of cognitive impairment with elevated cocaethylene levels and increased platelet aggregation found in cocaine abusers. 37 Chronic amphetamine users show deficits in a range of cognitive skills, including verbal fluency, pattern recognition, planning, and the ability to shift attention from one frame of reference to another. 38 The decision-making deficits observed in these individuals are similar to those with prefronto-cortical damage. 39 Prolonged but not recreational methamphetamine use (METH) induces cognitive deficits in neuropsychological tasks, motor function, and memory, which are only partially ameliorated following extended abstinence. 40 continued to score relatively poorly in tests of immediate and delayed word recall after extended abstinence. 41 Opiate (heroin, morphine, methadone, prescription pain killers) dependence is also well known to impair cognitive function. 42 Heroin dependence is associated with deficits in memory, attention, and impulse control. 38 Chronic pain patients and those in methadone maintenance also display comparable deficits in neuropsychological testing. 43 These deficits appear to be related in changes in functioning of the PFC. 38 Acute marijuana exposure results in reversible deficits in attention, memory, and decision making. 44 Accumulating evidence suggests that long-term, heavy cannabis use may cause enduring neuropsychological impairment that persists beyond the period of acute intoxication. 45 Studies of long-term, heavy cannabis users consistently show that these individuals perform worse on neuropsychological tests, 45 and some 46, 47 studies suggest that impairment may remain even after extended periods of abstinence. The magnitude and persistence of impairment may depend on factors such as the quantity, frequency, duration, and age of onset of cannabis use, as more severe and enduring impairment is evident among individuals with more frequent and prolonged heavy use and a younger age of onset. 48 Postulated mechanisms for cognitive decline include neurobiological adaptations to cannabinoid receptors in the CNS; structural differences in the hippocampus and other brain regions involved in cognitive functioning. 49 Prolonged cigarette smoking and smoking history are associated with cognitive decline, deficits in impulse control, and decision making. 50 In one study, smokers' cognitive speed declined nearly twice as much as nonsmokers' over 5 years. In addition, declines in smokers' cognitive flexibility and global cognition were significantly faster than that of nonsmokers. 51 Recent quitters' scores in these areas were similar to smokers, and ex-smokers performed at levels intermediate between smokers and nonsmokers. In another study, smokers' performance deteriorated more over 10 years than nonsmokers' on tests of verbal memory and attention. 52 Recent studies have suggested that neurotoxic effects from heavy cigarette smoking has an increased risk of dementia in current smokers, including Alzheimer's disease, vascular dementia, and can lead to greater declines in mental state testing compared to those who have never smoked cigarettes. 53 In addition to excessive alcohol and substance use exposures, comorbidities may contribute to cognitive decline. Diseases such as HF or exposure to chemotherapeutic agents may also increase the risk of cognitive decline.
HEART FAILURE
The prevalence of cognitive decline is high among patients with HF compared with healthy age and gender-matched controls. 54 HF with preserved and reduced ejection fraction is associated with defects in several domains of cognition. Another study suggests that cognitive difficulties in memory, reasoning, and processing speed may occur prior to HF diagnosis, while those with HF may experience steeper declines in reasoning over time as measured by the word series test. 55 A potential mechanism of HF-related cognitive decline involves the effect of increased angiotensin II in causing accelerated apoptosis of adult hippocampal cells. 56 Increased levels of angiotensin II leads to an increase in mitochondrial ROS and mitochondrial morphological changes as well as activation of AMP-activated protein kinase (AMPK) and consequently peroxisome proliferator-activated receptor gamma coactivator 1-alpha expression resulting in cell apoptosis.
Future research in this area should focus on identifying the mechanisms of cognitive decline in patients with HF and test therapies for improving cognition in this patient population.
CHEMOTHERAPEUTIC EXPOSURE
Cognitive decline has been reported by cancer survivors, particularly those who have received chemotherapy, and has been referred to as and longitudinal studies indicating that there may be a small subgroup of patients that experience chronic cognitive decline that continues after treatment. 57 Short-and long-term memory, speed of processing, attention and concentration, language, and executive functioning were domains reported by breast cancer survivors 1 year post treatment. 58 Heflin et al. 59 found that among 486 monozygotic geriatric twin pairs discordant for cancer, long-term cancer survivors were twice as likely to be diagnosed with dementia as their unaffected sibling.
However, studies in unrelated patients exposed to chemotherapy have resulted in conflicting results. 60 While there is no definitive evidence that chemotherapy increases the risk of developing dementia later in life, it is imperative to provide cognitive screening for patients undergoing chemotherapy and other forms of cancer treatment.
Future studies should aim to provide new knowledge on mechanisms of neurotoxicity with chemotherapy and evaluate regimens to prevent or ameliorate cognitive deficits during and after cancer treatment. 59 
HIV-ASSOCIATED NEUROCOGNITIVE DISORDER
Individuals with human immunodeficiency virus (HIV) often experience deficits in the domains of memory and executive functions during and after combined retroviral therapy (cART) that is referred to as HIV-associated neurocognitive disorders (HANDs). The manifestation of HAND can decrease adherence to pharmacotherapy, lower cognitive reserve, and increase the incidence of psychiatric comorbidities. 61 Longitudinal studies that have examined dysregulated sphingolipid and sterol metabolism in the central nervous system suggest that a progressive disorder of lipid metabolism that is similar to disorders of lipid storage may contribute to the pathogenesis of HAND. 61 Other studies have noted significant neuroinflammation in patients receiving range for fibromyalgia patients with cognitive complains for more than 7 years. 64 Nevertheless, this impact of cognitive symptoms for patients with FMS can be devastating and warrant further study to identify potential therapeutic strategies. 63 
IMPLICATIONS FOR NURSING PRACTICE
Nurses play a significant role in health promotion and disease prevention by providing education, support, and enhancing self-management skills of individuals and families. To promote cognitive health, nurses can encourage a healthy diet, active lifestyle, and adequate sleep as well as help individuals reduce harmful exposures that can contribute to cognitive decline. Individuals and families may have risk factors that are static, such as a cognitive risk allele or single nucleotide polymorphism, or risk factors that are dynamic, such as environmental risk factors that change over time. 65, 66 Recognizing that chronic conditions, such as HF, HIV, and fibromyalgia, may add vulnerability to accelerated cognitive decline, nurses can institute screening measures and interventions to optimize cognition and physical functioning for specific populations.
IMPLICATIONS FOR NURSING RESEARCH
Nursing research focused on identifying the mechanisms of cognitive decline and designing interventions to reduce intrinsic and extrinsic risk factors and/or integrate protective strategies to help preserve cognitive over time will contribute to population health. A deeper understanding of the mechanisms of cognitive decline and the quantification of exposures over time could lead to more precise preventative or treatment interventions. Knowledge regarding how chronic conditions increase vulnerability to cognitive decline could lead to innovative disease-management strategies that incorporate cognitive health interventions early on in the course of the disease. Innovations in tracking cognitive health using biomarkers and/or technology may lead to better identification of those at risk and help facilitate timely interventions that focus on delaying decline and preserving cognition and function for as long as possible.
CONCLUSIONS
Recent advances in the study of cognitive decline as an aspect of aging or associated with chronic comorbidities highlight the complex nature of studying cognition across populations. The various definitions of cognitive decline as well as the intrinsic and extrinsic factors that impact cognition over the life span should be considered in future clinical research studies ( Figure 1 ). As more information is gleaned from studies that identify specific mechanisms associated with cognitive decline, there may be more direct methods of quantifying vulnerability over the life span that could lead to more informed decision making by individuals regarding their treatments and lifestyle choices. Conditions in which cognitive deficits are perceived by individuals but for which no direct mechanism can be identified may still benefit from adhering to cognition-preserving strategies. Nurses working with patients who are at risk of cognitive decline or report cognitive disturbances can use this information to discuss lifestyle choices that impact cognition and various strategies for improving cognitive and physical functioning over the life span.
